Alexandria Venture Investments

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying causes of thrombosis and type one diabetes. By leveraging a deep understanding of the molecular mechanisms associated with these conditions, the company seeks to create innovative treatment options that can lead to improved health outcomes for patients. Their focus includes therapies specifically targeting heparin-induced thrombocytopenia and thrombosis, with the goal of providing patients with effective solutions for complete recovery from diabetes and associated complications.

miRecule, Inc. is a biotechnology company specializing in the development of microRNA-based therapeutics, with a focus on addressing challenges in cancer treatment and other diseases such as muscular dystrophy. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company has created a drug discovery platform called DREAmiR. This platform leverages genomic and outcome data from thousands of patients to identify genetic changes linked to diseases. It combines genomic sequencing, expression, and prognostic data from cancer patients with high-throughput screening data to pinpoint microRNA candidates for replacement therapy. miRecule's approach aims to formulate these candidates into tumor-targeted nanoparticles, enabling oncologists to effectively target and eliminate drug-resistant cancer cells.

miRecule, Inc. is a biotechnology company specializing in the development of microRNA-based therapeutics, with a focus on addressing challenges in cancer treatment and other diseases such as muscular dystrophy. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company has created a drug discovery platform called DREAmiR. This platform leverages genomic and outcome data from thousands of patients to identify genetic changes linked to diseases. It combines genomic sequencing, expression, and prognostic data from cancer patients with high-throughput screening data to pinpoint microRNA candidates for replacement therapy. miRecule's approach aims to formulate these candidates into tumor-targeted nanoparticles, enabling oncologists to effectively target and eliminate drug-resistant cancer cells.

Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.

Vtesse, Inc. develops drugs for patients suffering from rare diseases. The company focuses on conducting the clinical study of VTS-270 for the treatment of Niemann-Pick disease type C (NPC), as well as on conducting pre-clinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases. Vtesse, Inc. is based in Gaithersburg, Maryland. As of April 3, 2017, Vtesse, Inc. operates as a subsidiary of Sucampo Pharmaceuticals, Inc.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, dedicated to discovering and developing innovative immunomedicines for cancer and other immune-related diseases. The company’s lead product candidate, NC318, is currently undergoing Phase 2 clinical trials aimed at treating advanced or metastatic solid tumors. Additionally, NextCure is advancing NC410, an immunomedicine designed to counteract immune suppression through targeting an immune modulator known as Leukocyte-Associated Immunoglobulin-like Receptor 1. The company is also engaged in research programs evaluating novel immunomodulatory molecules, including antibodies in preclinical development that target specific immune modulators in inflamed tissues and tumor microenvironments. NextCure has established a license agreement with Yale University and collaborates with Eli Lilly and Company for research and development efforts. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets and develop first-in-class immunotherapy products.

WellDoc, Inc. is a digital health company focused on chronic disease management, particularly diabetes care. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc offers innovative solutions such as the DiabetesManager platform and BlueStar mobile prescription therapy. The DiabetesManager platform facilitates patient-provider coordination through features like personalized coaching, medication reminders, and real-time alerts, while BlueStar offers patients immediate guidance to enhance self-management of diabetes. WellDoc’s services also include clinical decision support for healthcare professionals and a comprehensive suite of technical services, such as software development and regulatory management. The company aims to improve health outcomes and reduce healthcare costs by integrating behavioral and motivational applications with everyday technology. WellDoc serves a diverse range of clients, including payors, employers, pharmaceutical and medical device companies, and healthcare providers.

Vtesse, Inc. develops drugs for patients suffering from rare diseases. The company focuses on conducting the clinical study of VTS-270 for the treatment of Niemann-Pick disease type C (NPC), as well as on conducting pre-clinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases. Vtesse, Inc. is based in Gaithersburg, Maryland. As of April 3, 2017, Vtesse, Inc. operates as a subsidiary of Sucampo Pharmaceuticals, Inc.